Since KDM6B inhibition appears to affect its antitumor activity through downregulation of the E2F transcriptome, we hypothesized that high levels of the E2F transcriptome may correlate with the response of cancer cells to KDM6B inhibition. Here, KDM6B is linked to cancer.